New 'Smart Bomb' drug targets Hard-to-Treat cancers
NCT ID NCT07460375
Summary
This study is testing a new drug called LCB02A for people with advanced solid tumors that have a specific protein marker called CLDN18.2. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for people whose cancer has not responded to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASAN Medical Center
Seoul, 05505, South Korea
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact
-
Medical University of South Carolina
Charleston, South Carolina, 29406, United States
Contact
-
Princess Margaret Hospital
Toronto, Ontario, M5S 3H2, Canada
Contact
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
Contact
Conditions
Explore the condition pages connected to this study.